术前总胆固醇和高密度脂蛋白胆固醇水平对乳腺癌患者预后的影响

李成伟; 乔梦祥; 刘铁成; 金功圣

doi:10.16766/j.cnki.issn.1674-4152.002457

术前总胆固醇和高密度脂蛋白胆固醇水平对乳腺癌患者预后的影响

doi: 10.16766/j.cnki.issn.1674-4152.002457

蚌埠医学院第一附属医院肿瘤外科，安徽蚌埠 233004

基金项目:

安徽省高校自然科学基金项目 KJ2019A0352

详细信息

通讯作者:
金功圣，E-mail：jgs2007@qq.com

中图分类号: R737.9 R446.112
计量
- 文章访问数: 251
- HTML全文浏览量: 175
- PDF下载量: 9
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-15
- 网络出版日期: 2022-09-05

Effect of preoperative total cholesterol and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer

Department of Oncology Surgery, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

摘要

摘要: 目的通过测定乳腺癌患者术前血清总胆固醇及高密度脂蛋白胆固醇水平，探讨术前总胆固醇及高密度脂蛋白胆固醇水平对乳腺癌患者预后的影响。方法回顾性收集2012年1月—2014年12月蚌埠医学院第一附属医院341例经病理确诊的乳腺癌患者清晨空腹多项血脂数据及临床病理资料，采用Kaplan-Meier分析法和Cox比例风险回归模型分析乳腺癌患者的总体生存期(OS)及无病生存期(DFS)。结果患者TC水平 < 6.2 mmol/L的平均OS为96.2个月，患者TC水平≥6.2 mmol/L的平均OS为95.4个月(P=0.556)，患者TC水平 < 6.2 mmol/L的平均DFS为95.9个月，患者TC水平≥6.2 mmol/L的平均DFS为94.0个月(P=0.122)。在不同水平的TC组中，总体生存率及无病生存率差异均无统计学意义。患者HDL-C水平 < 1.04 mmol/L的平均OS为94.7个月，患者HDL-C水平≥1.04 mmol/L的平均OS为97.6个月(P=0.019)，患者HDL-C水平 < 1.04 mmol/L的平均DFS为93.2个月，而患者HDL-C水平≥1.04 mmol/L的平均DFS为97.6个月(P=0.003)。在不同水平的HDL-C组中，总体生存期及无病生存期差异均有统计学意义。COX多因素分析发现，高水平HDL-C患者DFS更长(HR=3.916，95%CI：1.355~11.313, P=0.012)。结论术前HDL-C水平可能是预测乳腺癌患者DFS的独立因素。
- 乳腺癌 /
- 血脂水平 /
- 预后
Abstract: Objective To determine serum total cholesterol (TC) and high-density lipoprotein-cholesterol (HDL-C) of patients with breast cancer, explore the effect of preoperative blood lipid levels on the prognosis of patients with breast cancer. Methods Fasting plasma lipid in the morning and clinical pathological data of 341 patients with breast cancer confirmed by pathology from January 2012 to December 2014 in the First Affiliated Hospital of Bengbu Medical College were collected retrospectively. Kaplan-Meier analysis and Cox proportional hazard regression model were used to analyse overall survival (OS) and disease-free survival (DFS). Results The average OS of patients with TC < 6.2 mmol/L was 96.2 months, whereas that of patients with TC≥6.2 mmol/L was 95.4 months (P=0.556). The average DFS of patients with TC < 6.2 mmol/L was 95.9 months, and that of patients with TC≥6.2 mmol/L was 94.0 months (P=0.122). In different levels of TC groups, the OS rate and DFS rate were not statistically significant. The average OS of patients with HDL-C < 1.04 mmol/L was 94.7 months, whereas that of patients with HDL-C≥1.04 mmol/L was 97.6 months (P=0.019). The average DFS of patients with HDL-C < 1.04 mmol/L was 93.2 months, whereas the average DFS of patients with HDL-C level≥1.04 mmol/L was 94.7 months (P=0.003). In different levels of HDL-C groups, the OS time and DFS time were statistically significant. COX multivariate analysis showed that high HDL-C was beneficial to DFS (HR=3.916, 95% CI: 1.355-11.313, P=0.012). Conclusion The preoperative HDL-C level may be an independent factor predicting DFS in patients with breast cancer.
- Breast cancer /
- Blood lipid level /
- Prognosis

HTML全文

图 1 不同TC水平的总体生存期的K-M曲线

Figure 1. Overall survival curves of K-M at different levels of TC

下载: 全尺寸图片幻灯片

图 2 不同TC水平的无疾病生存期的K-M曲线

Figure 2. Curves of disease-free survival with K-M at different levels of TC

下载: 全尺寸图片幻灯片

图 3 不同HDL-C水平的总体生存期的K-M曲线

Figure 3. Overall survival curves of K-M with different levels of HDL-C

下载: 全尺寸图片幻灯片

图 4 不同HDL-C水平的无疾病生存期的K-M曲线

Figure 4. Curves of disease-free survival with different levels of HDL-C and K-M

下载: 全尺寸图片幻灯片

表 1 341例乳腺癌患者临床病理特征

Table 1. Clinicopathological features of 341 patients with breast cancer

项目	类别	例数	百分比(%)
年龄(岁)	≥45	202	59.2
	< 45	139	40.8
月经状态	未绝经	138	40.5
	绝经	203	59.5
肿瘤分期	T1	167	49.0
	T2	153	44.9
	T3	18	5.3
	T4	3	0.9
淋巴结分期	N0	163	47.8
	N1	88	25.8
	N2	78	22.9
	N3	12	3.5
分子分型	Luminal A型	61	17.9
	Luminal B型	112	32.8
	HER-2阳性型	86	25.2
	TNBC型	82	24.0
TC(mmol/L)	≥6.2	110	32.3
	< 6.2	231	67.7
TG(mmol/L)	≥2.3	90	26.4
	< 2.3	251	73.6
HDL-C(mmol/L)	≥1.04	108	32.3
	< 1.04	233	68.3
LDL-C(mmol/L)	≥3.4	113	33.1
	< 3.4	228	66.9

下载: 导出CSV

表 2 341例乳腺癌患者不同TC水平与临床特征的关系(例)

Table 2. Relationship between different TC levels and clinical features in 341 breast cancer patients (cases)

项目	TC		统计量	P值
项目	≥6.2 mmol/L(n=110)	< 6.2 mmol/L(n=231)	统计量	P值
年龄			10.643^a	0.001
≥45岁	31	108
< 45岁	79	123
月经状态			13.355^a	0.001
未绝经	60	78
绝经	50	153
肿瘤分期			7.935^b	0.005
T1	45	122
T2	50	103
T3	13	5
T4	2	1
淋巴结分期			8.190^b	0.004
N0	43	120
N1	28	60
N2	30	48
N3	9	3
分子分型			2.470^a	0.481
Luminal A型	17	44
Luminal B型	34	78
HER-2阳性型	27	59
TNBC型	32	50
注：^a为χ²值，^b为H值。

下载: 导出CSV

表 3 341例乳腺癌患者不同HDL-C水平与临床特征的关系(例)

Table 3. Relationship between levels of different HDL-C and clinical features in 341 Patients with breast cancer (cases)

项目	HDL-C		统计量	P值
项目	≥1.04 mmol/L(n=108)	< 1.04 mmol/L(n=233)	统计量	P值
年龄			0.219^a	0.640
≥45岁	46	93
< 45岁	62	140
月经状态			2.530^a	0.112
未绝经	37	101
绝经	71	132
肿瘤分期			14.800^b	< 0.001
T1	69	98
T2	36	117
T3	3	15
T4	0	3
淋巴结分期			0.550^b	0.457
N0	52	111
N1	33	55
N2	21	57
N3	2	10
分子分型			3.385^a	0.336
Luminal A型	24	37
Luminal B型	38	74
HER-2阳性型	23	63
TNBC型	23	59
注：^a为χ²值，^b为H值。

下载: 导出CSV

表 4 341例乳腺癌患者总体生存期、无疾病生存期的单因素Cox回归分析

Table 4. Univariate Cox regression analysis of overall survival and disease-free survival in 341 breast cancer patients

项目	OS单因素分析			DFS单因素分析
项目	HR值	95% CI	P值	HR值	95% CI	P值
年龄	0.830	0.376~1.832	0.645	0.853	0.386~1.882	0.693
月经状态	0.649	0.293~1.436	0.286	0.635	0.287~1.402	0.261
分子分型	1.339	0.906~1.980	0.143	1.335	0.909~1.961	0.141
TC水平	0.780	0.340~2.387	0.557	0.525	0.229~1.204	0.128
TG水平	0.513	0.227~1.160	0.109	0.315	0.140~0.709	0.005
HDL-C水平	3.086	1.148~8.295	0.025	4.294	1.541~11.964	0.005
LDL-C水平	0.419	0.191~0.921	0.030	0.306	0.139~0.678	0.030

下载: 导出CSV

表 5 341例乳腺癌患者总体生存期、无疾病生存期多因素Cox比例分析

Table 5. Multivariate Cox ratio analysis of overall survival and disease-free survival in 341 breast cancer patients

项目	OS多因素分析			DFS多因素分析
项目	HR值	95% CI	P值	HR值	95% CI	P值
TG水平				0.408	0.175~0.951	0.038
HDL-C水平	2.673	0.977~7.309	0.055	3.916	1.355~11.313	0.012
LDL-C水平	0.503	0.226~1.121	0.093	0.412	0.180~0.946	0.037

下载: 导出CSV

参考文献(24)

[1]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
[2]	SUN Y S, ZHAO Z, YANG Z N, et al. Risk factors and preventions of breast cancer[J]. Int J Biol Med Sci, 2017, 13(11): 1387. doi: 10.7150/ijbs.21635
[3]	KABAT G C, KIM M Y, CHLEBOWSKI R T, et al. Serum lipids and risk of obesity-related cancers in postmenopausal women[J]. Cancer Causes Control, 2018, 29(1): 13-24. doi: 10.1007/s10552-017-0991-y
[4]	NELSON E R. The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer[J]. Mol Cell Endocrinol, 2018, 466: 73-80. doi: 10.1016/j.mce.2017.09.021
[5]	邓赢芳, 王淼舟. 血脂水平与乳腺癌关系的研究现状和进展[J]. 临床医药文献电子杂志, 2019, 6(5): 1. doi: 10.3877/j.issn.2095-8242.2019.05.001 DENG Y F, WANG M Z. Research status and progress of the relationship between blood lipid level and breast cancer[J]. Journal of Clinical Medical Literature (ElectronicEdition), 2019, 6(5): 1. doi: 10.3877/j.issn.2095-8242.2019.05.001
[6]	MAZZUFERI G, BACCHETTI T, ISLAM M O, et al. High density lipoproteins and oxidative stress in breast cancer[J]. Lipids Health Dis, 2021, 20(1): 1-13. doi: 10.1186/s12944-020-01429-x
[7]	TRYGVE L, MORTENSEN E S, HAWA N, et al. Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes[J]. Bmc Cancer, 2018, 18(1): 1-11. doi: 10.1186/s12885-017-3892-2
[8]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202110015.htm Breast Cancer Committee of Chinese Anti-Cancer Association. Chinese Anti-Cancer Association Guidelines and Specifications for Diagnosis and Treatment of Breast Cancer (2021 edition)[J]. China Oncology, 2021, 31(10): 954-1040. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202110015.htm
[9]	中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华健康管理学杂志, 2017, 11(1): 7-28. doi: 10.3760/j.issn.1674-0815.2017.01.003 Joint Committee on the Revision of Guidelines for Prevention and Treatment of dyslipidemia in Adults in China. 2016 Chinese guideline for the management of dyslipidemia in adults[J]. Chinese Journal of Health Management, 2017, 11(1): 7-28. doi: 10.3760/j.issn.1674-0815.2017.01.003
[10]	潘婉婉, 董孟浩, 余发智, 等. 外周血炎症指标NLR、PLR、LMR预测乳腺癌新辅助化疗疗效的价值[J]. 中华全科医学, 2021, 19(9): 1442-1446. doi: 10.16766/j.cnki.issn.1674-4152.002081 PAN W W, DONG M H, YU F Z, et al. Value of peripheral inflammatory markers NLR, PLR and LMR in predicting the efficacy of neoadjuvant chemotherapy for breast cancer[J]. Chinese general practice, 2021, 19(9): 1442-1446. doi: 10.16766/j.cnki.issn.1674-4152.002081
[11]	NOWAK C, ǍRNLÖV J. A Mendelian randomization study of the effects of blood lipids on breast cancer risk[J]. Nat Commun, 2018, 9(1): 1-7. doi: 10.1038/s41467-017-02088-w
[12]	WANG Y Y, ATTANÉ C, MILHAS D, et al. Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells[J]. JCI Insight, 2017, 2(4): e87489. DOI: 10.1172/jci.insight.87489.
[13]	张艳利, 陈茂山, 杨光伦. 血清血脂和脂蛋白水平与乳腺癌发生及其临床病理学特征的相关性分析[J]. 中国普外基础与临床杂志, 2018, 25(2): 171-177. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201802009.htm ZHANG Y L, CHEN M S, YANG G L. Association analysis of serum lipids and lipoprotein levels with the occurrence of breast cancer and clinicopathological characteristics of breast cancer patients[J]. Chinese Journal of Bases and Clinics in General Surgery, 2018, 25(2): 171-177. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201802009.htm
[14]	CHIMENTO A, CASABURI I, AVENA P, et al. Cholesterol and its metabolites in tumor growth: Therapeutic potential of statins in cancer treatment[J]. Front Endocrinol, 2019, 9: 807. doi: 10.3389/fendo.2018.00807
[15]	MUNIR M T, PONCE C, POWELL C A, et al. The contribution of cholesterol and epigenetic changes to the pathophysiology of breast cancer[J]. J Steroid Biochem Mol Biol, 2018, 183: 1-9. doi: 10.1016/j.jsbmb.2018.05.001
[16]	WU J, LEI X, PAN X, et al. Association between serum lipids and breast cancer risk in premenopausal women: Systematic review and meta-analysis[J]. J Int Med Res, 2021, 49(11). DOI: 10.1177/03000605211061033.
[17]	GUAITA-ESTERUELAS S, GUMA J, MASANA L, et al. The peritumoural adipose tissue microenvironment and cancer. The roles of fatty acid binding protein 4 and fatty acid binding protein 5[J]. Mol Cell Endocrinol, 2018, 462: 107-118. doi: 10.1016/j.mce.2017.02.002
[18]	SHEIKHPOUR E, NOORBAKHSH P, FOROUGHI E, et al. A survey on the role of interleukin-10 in breast cancer: A narrative[J]. Rep Biochem Mol Biol, 2018, 7(1): 30-37.
[19]	黄赞. 脂质代谢, 体质量指数与乳腺癌发生的关系[J]. 中国实用医药, 2019, 14(27): 3-5. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201927002.htm HUANG Z. Correlation of lipid metabolism, body mass index and breast cancer[J]. Practical medicine in China, 2019, 14(27): 3-5. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201927002.htm
[20]	OZMEN H K, ERDEMCI B, ASKIN S, et al. Carnitine and adiponectin levels in breast cancer after radiotherapy[J]. Open Med, 2017, 12: 189-194. doi: 10.1515/med-2017-0028
[21]	于子棋, 肖志, 邬玉辉, 等. 乳腺癌患者化疗前后血脂血糖及体质量指数的变化[J]. 中国普通外科杂志, 2017, 26(11): 1502-1505. doi: 10.3978/j.issn.1005-6947.2017.11.022 YU Z Q, XIAO Z, WU Y H, et al. Changes of blood lipid, blood glucose and body mass index in breast cancer patients before and after chemotherapy[J]. Chinese Journal of General Surgery, 2017, 26(11): 1502-1505. doi: 10.3978/j.issn.1005-6947.2017.11.022
[22]	ALOMAR S A, GǍMAN M A, PRABAHAR K, et al. The effect of tamoxifen on the lipid profile in women: A systematic review and meta-analysis of randomized controlled trials[J]. Exp Gerontol, 2022, 159: 111680. DOI: 10.1016/j.exger.2021.111680.
[23]	李江涛. 研究阿那曲唑对乳腺癌术后化疗患者血脂、肝功能的影响[J]. 北方药学, 2018, 15(6): 29. https://www.cnki.com.cn/Article/CJFDTOTAL-BFYX201806020.htm LI J T. To study the effect of anastrozole on blood lipid and liver function in patients with breast cancer undergoing postoperative chemotherapy[J]. Journal of North Pharmacy, 2018, 15(6): 29. https://www.cnki.com.cn/Article/CJFDTOTAL-BFYX201806020.htm
[24]	JI Y L, ROUNDS T, CROCKER A, et al. The effect of atorvastatin on breast cancer biomarkers in high-risk women[J]. Cancer Prev Res, 2016, 9(5): 379-384. doi: 10.1158/1940-6207.CAPR-15-0300